시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 크리티컬 케어 항부정맥약 시장 보고서(2025년)
Critical Care Antiarrhythmic Drugs Global Market Report 2025
상품코드 : 1703249
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,371,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,209,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,048,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

크리티컬 케어 항부정맥약 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 6.2%의 연평균 복합 성장률(CAGR)로 13억 7,000만 달러 규모에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 정밀의료 채택 증가, 심혈관 질환 발병률 증가, 신흥 시장 및 의료 인프라, 새로운 치료법의 규제 승인, 환자의 안전과 효과에 대한 관심 증가 등에 기인합니다. 예측 기간 중 주요 동향으로는 약물전달 기술 혁신, 심장 모니터링 기술 혁신, 디지털 헬스 솔루션의 통합, 병용 요법으로의 전환, 비약물학적 중재 등이 있습니다.

심혈관 질환의 유병률 증가는 중환자 치료 항부정맥제 시장의 성장을 가속할 것으로 예상됩니다. 심혈관 질환은 심장과 혈관에 영향을 미치고 심장마비, 뇌졸중과 같은 합병증을 유발하는 질환을 포함합니다. 좌식 생활습관, 식습관 장애, 흡연, 비만과 고혈압 증가 등 여러 요인이 심혈관 질환의 유병률 증가에 기여하고 있습니다. 심혈관 질환 환자의 생명을 위협하는 부정맥을 관리하고, 정상적인 심장 리듬을 회복하고, 심장마비를 예방하기 위해 중환자 치료용 항부정맥제는 매우 중요합니다. 예를 들어 스위스에 본부를 둔 비정부기구인 세계심장연맹에 따르면 CVD로 인한 사망자 수로 측정되는 심혈관 질환의 부담은 2020년 추정 1,890만 명에서 2030년 2,220만 명 이상, 2050년 3,230만 명 이상으로 증가할 것으로 예측했습니다. 그 결과, 심혈관 질환의 유병률 증가가 중환자 치료용 항부정맥제 시장의 성장에 박차를 가하고 있습니다.

중환자 치료용 항부정맥제 시장의 주요 업체들은 경쟁 우위를 확보하기 위해 멕시틸의 치료제에 해당하는 첨단 제품을 개발하고 있습니다. 멕시틸은 심장 조직의 나트륨 채널을 차단하여 심장의 전기적 활동을 안정화시켜 심실성 부정맥과 같은 불규칙한 심장 리듬을 조절하는 데 도움이 되는 항부정맥제입니다. 예를 들어 2022년 1월 미국 제약사 세노아즈 파마슈티컬스(Senors Pharmaceuticals Inc.)는 미국 시장에서 멕시레틴 염산염 캡슐 USP를 150mg, 200mg, 250mg 용량으로 출시했습니다. 이 캡슐은 생명을 위협할 수 있는 지속성 심실빈맥을 포함한 확인된 심실성 부정맥을 관리하기 위해 멕시스틸(멕시레틴 염산염)을 대체하는 치료제로 처방됩니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Critical care antiarrhythmic drugs are medications utilized in critical care settings to manage life-threatening cardiac arrhythmias such as ventricular fibrillation and ventricular tachycardia. Administered intravenously, these drugs act swiftly to restore normal heart rhythm and prevent cardiac arrest, playing a crucial role in stabilizing patients with severe cardiac rhythm disturbances.

These drugs encompass several types including beta blockers, calcium channel blockers, sodium channel blockers, potassium channel blockers, and others. Beta blockers, for instance, function by blocking adrenaline effects, thereby lowering heart rate and blood pressure. They are employed across various settings such as hospitals, clinics, and ambulatory centers to treat conditions such as ventricular arrhythmias and supraventricular arrhythmias.

The critical care antiarrhythmic drug market research report is one of a series of new reports from The Business Research Company that provides critical care antiarrhythmic drug market statistics, including critical care antiarrhythmic drug industry global market size, regional shares, competitors with a critical care antiarrhythmic drug market share, detailed critical care antiarrhythmic drug market segments, market trends and opportunities, and any further data you may need to thrive in the critical care antiarrhythmic drug industry. This critical care antiarrhythmic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The critical care antiarrhythmic drugs market size has grown strongly in recent years. It will grow from $1.01 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increased prevalence of cardiac arrhythmias, expansion of critical care facilities, regulatory approvals, and guidelines, growing healthcare expenditure, and public health initiatives for cardiac care.

The critical care antiarrhythmic drugs market size is expected to see strong growth in the next few years. It will grow to $1.37 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the increasing adoption of precision medicine, rising incidence of cardiovascular diseases, emerging markets and healthcare infrastructure, regulatory approvals for novel therapies, and focus on patient safety and efficacy. Major trends in the forecast period include technological innovations in drug delivery, technological innovations in cardiac monitoring, integration of digital health solutions, a shift towards combination therapies, and non-pharmacological interventions.

The rising prevalence of cardiovascular disease is expected to drive the growth of the critical care antiarrhythmic drugs market. Cardiovascular disease encompasses conditions affecting the heart or blood vessels, leading to complications such as heart attacks or strokes. Several factors contribute to the increasing prevalence of cardiovascular disease, including sedentary lifestyles, poor dietary habits, smoking, and rising rates of obesity and hypertension. Critical care antiarrhythmic drugs are crucial for managing life-threatening cardiac arrhythmias, restoring normal heart rhythm, and preventing cardiac arrest in patients with cardiovascular disease. For instance, according to the World Heart Federation, a Switzerland-based non-governmental organization, the burden of cardiovascular disease, measured by the number of CVD deaths, is projected to rise from an estimated 18.9 million in 2020 to over 22.2 million in 2030 and 32.3 million in 2050. Consequently, the increasing prevalence of cardiovascular disease is fueling the growth of the critical care antiarrhythmic drugs market.

Leading companies in the critical care antiarrhythmic drugs market are developing advanced products, such as the therapeutic equivalent of Mexitil, to gain a competitive advantage. Mexitil is an antiarrhythmic medication that stabilizes the heart's electrical activity by blocking sodium channels in cardiac tissues, helping regulate irregular heart rhythms such as ventricular arrhythmias. For example, in January 2022, Senores Pharmaceuticals Inc., a US-based pharmaceutical company, launched Mexiletine Hydrochloride Capsules USP in strengths of 150 mg, 200 mg, and 250 mg in the U.S. market. These capsules serve as a therapeutic alternative to MEXITIL (Mexiletine Hydrochloride) and are prescribed for managing confirmed ventricular arrhythmias, including sustained ventricular tachycardia, which pose life-threatening risks.

In April 2022, Melinta Therapeutics LLC, a US-based pharmaceutical company, acquired the U.S. rights to TOPROL-XL (metoprolol succinate) and its Authorized Generic (AG) from New American Therapeutics Inc. for an undisclosed amount. This acquisition expands and diversifies Melinta's existing portfolio and supports its long-term growth strategy and profitability. New American Therapeutics Inc. is a US-based specialty pharmaceutical company that provides critical-care antiarrhythmic drugs.

Major companies operating in the critical care antiarrhythmic drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., Bristol Myers Squibb, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals Plc, Amneal Pharmaceuticals Inc., Lupin Pharmaceutical Limited, Biocon Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Upsher-Smith Laboratories LLC., Mayne Pharma International Pty Ltd., Zydus Cadila Healthcare Limited, Amomed Pharma GmbH

North America was the largest region in the critical care antiarrhythmic drugs market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the critical care antiarrhythmic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the critical care antiarrhythmic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The critical care antiarrhythmic drugs market consists of sales of drugs such as amiodarone, lidocaine, and procainamide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Critical Care Antiarrhythmic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on critical care antiarrhythmic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for critical care antiarrhythmic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The critical care antiarrhythmic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Critical Care Antiarrhythmic Drugs Market Characteristics

3. Critical Care Antiarrhythmic Drugs Market Trends And Strategies

4. Critical Care Antiarrhythmic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Critical Care Antiarrhythmic Drugs Growth Analysis And Strategic Analysis Framework

6. Critical Care Antiarrhythmic Drugs Market Segmentation

7. Critical Care Antiarrhythmic Drugs Market Regional And Country Analysis

8. Asia-Pacific Critical Care Antiarrhythmic Drugs Market

9. China Critical Care Antiarrhythmic Drugs Market

10. India Critical Care Antiarrhythmic Drugs Market

11. Japan Critical Care Antiarrhythmic Drugs Market

12. Australia Critical Care Antiarrhythmic Drugs Market

13. Indonesia Critical Care Antiarrhythmic Drugs Market

14. South Korea Critical Care Antiarrhythmic Drugs Market

15. Western Europe Critical Care Antiarrhythmic Drugs Market

16. UK Critical Care Antiarrhythmic Drugs Market

17. Germany Critical Care Antiarrhythmic Drugs Market

18. France Critical Care Antiarrhythmic Drugs Market

19. Italy Critical Care Antiarrhythmic Drugs Market

20. Spain Critical Care Antiarrhythmic Drugs Market

21. Eastern Europe Critical Care Antiarrhythmic Drugs Market

22. Russia Critical Care Antiarrhythmic Drugs Market

23. North America Critical Care Antiarrhythmic Drugs Market

24. USA Critical Care Antiarrhythmic Drugs Market

25. Canada Critical Care Antiarrhythmic Drugs Market

26. South America Critical Care Antiarrhythmic Drugs Market

27. Brazil Critical Care Antiarrhythmic Drugs Market

28. Middle East Critical Care Antiarrhythmic Drugs Market

29. Africa Critical Care Antiarrhythmic Drugs Market

30. Critical Care Antiarrhythmic Drugs Market Competitive Landscape And Company Profiles

31. Critical Care Antiarrhythmic Drugs Market Other Major And Innovative Companies

32. Global Critical Care Antiarrhythmic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Critical Care Antiarrhythmic Drugs Market

34. Recent Developments In The Critical Care Antiarrhythmic Drugs Market

35. Critical Care Antiarrhythmic Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기